A Timely shift from shotgun to targeted proteomics and how it can be groundbreaking for cancer research

Frontiers in Oncology

Volumn 7, Issue FEB, 2017, Pages

  Faria, Sara S ^a   Morris, Carlos F M ^b   Silva, Adriano R ^b   Fonseca, Micaella P ^b,c   Forget, Patrice ^d   Castro, Mariana S ^b   Fontes, Wagner ^b  

^a FEDERAL UNIVERSITY OF UBERLÂNDIA   (Brazil)

^b UNIVERSITY OF BRASILIA   (Brazil)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^d UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

Biomarkers; Cancer; Diagnosis; Mass spectrometry; Targeted proteomics

Indexed keywords

CD74 ANTIGEN; STAT PROTEIN; TUMOR MARKER;

ARTICLE; BREAST CANCER; CANCER MORTALITY; CANCER RESEARCH; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENE SEQUENCE; HUMAN; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; LIVER CELL CARCINOMA; LUNG CANCER; MASS SPECTROMETRY; OVARY CARCINOMA; PANCREAS CANCER; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEIN PROTEIN INTERACTION; PROTEOMICS; SHOTGUN PROTEOMICS; TARGETED PROTEOMICS; THYROID TUMOR; WESTERN BLOTTING;

EID: 85014631062     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2017.00013     Document Type: Article

References (176)

1. Deen KI, Silva H, Deen R, Chandrasinghe PC. Colorectal cancer in the young, many questions, few answers. World J Gastrointest Oncol (2016) 8:481-8. doi:10.4251/wjgo.v8.i6.481
2. Favoriti P, Carbone G, Greco M, Pirozzi F, Pirozzi REM, Corcione F. Worldwide burden of colorectal cancer: a review. Updates Surg (2016) 68:7-11. doi:10.1007/s13304-016-0359-y
3. Torre LA, Siegel RL, Jemal A. Lung cancer statistics. Adv Exp Med Biol (2016) 893:1-19. doi:10.1007/978-3-319-24223-1_1
4. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer (2015) 136:E359-86. doi:10.1002/ijc.29210
5. Fan YS. Companion diagnostic testing for targeted cancer therapies: an overview. Genet Test Mol Biomarkers (2013) 17:515-23. doi:10.1089/gtmb.2012.0510
6. Keedy VL, Temin S, Somerfield MR, Beasley MB, Johnson DH, McShane LM, et al. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol (2011) 29:2121-7. doi:10.1200/JCO.2010.31.8923
7. Topol EJ. Individualized medicine from prewomb to tomb. Cell (2014) 157:241-53. doi:10.1016/j.cell.2014.02.012
8. Morris CF, Tahir M, Arshid S, Castro MS, Fontes W. Reconciling the IPC and two-hit models: dissecting the underlying cellular and molecular mechanisms of two seemingly opposing frameworks. J Immunol Res (2015) 2015:697193. doi:10.1155/2015/697193
9. Picotti P, Bodenmiller B, Aebersold R. Proteomics meets the scientific method. Nat Methods (2013) 10:24-7. doi:10.1038/nmeth.2291
10. Rai AJ, Gelfand CA, Haywood BC, Warunek DJ, Yi J, Schuchard MD, et al. HUPO plasma proteome project specimen collection and handling: towards the standardization of parameters for plasma proteome samples. Proteomics (2005) 5:3262-77. doi:10.1002/pmic.200401245
11. Elschenbroich S, Ignatchenko V, Clarke B, Kalloger SE, Boutros PC, Gramolini AO, et al. In-depth proteomics of ovarian cancer ascites: combining shotgun proteomics and selected reaction monitoring mass spectrometry. J Proteome Res (2011) 10:2286-99. doi:10.1021/pr1011087
12. Aebersold R, Burlingame AL, Bradshaw RA. Western blots versus selected reaction monitoring assays: time to turn the tables? Mol Cell Proteomics (2013) 12:2381-2. doi:10.1074/mcp.E113.031658
13. Maiolica A, Junger MA, Ezkurdia I, Aebersold R. Targeted proteome investigation via selected reaction monitoring mass spectrometry. J Proteomics (2012) 75:3495-513. doi:10.1016/j.jprot.2012.04.048
14. Clauser KR, Hall SC, Smith DM, Webb JW, Andrews LE, Tran HM, et al. Rapid mass spectrometric peptide sequencing and mass matching for characterization of human melanoma proteins isolated by two-dimensional PAGE. Proc Natl Acad Sci U S A (1995) 92:5072-6.
15. Ang C-S, Rothacker J, Patsiouras H, Gibbs P, Burgess AW, Nice EC. Use of multiple reaction monitoring for multiplex analysis of colorectal cancer-associated proteins in human feces. Electrophoresis (2011) 32:1926-38. doi:10.1002/elps.201000502
16. Chen J, Wu W, Chen L, Zhou H, Yang R, Hu L, et al. Profiling the potential tumor markers of pancreatic ductal adenocarcinoma using 2D-DIGE and MALDI-TOF-MS: up-regulation of complement C3 and alpha-2-HS-glycoprotein. Pancreatology (2013) 13:290-7. doi:10.1016/j.pan.2013.03.010
17. Milioli HH, Sousa KS, Kaviski R, Oliveira NCDS, Urban CDA, De Lima RS, et al. Comparative proteomics of primary breast carcinomas and lymph node metastases outlining markers of tumor invasion. Cancer Genomics Proteomics (2015) 12:89-101.
18. Guo L, Zhang C, Zhu J, Yang Y, Lan J, Su G, et al. Proteomic identification of predictive tissue biomarkers of sensitive to neoadjuvant chemotherapy in squamous cervical cancer. Life Sci (2016) 151:102-8. doi:10.1016/j.lfs.2016.03.006
19. Rogowska-Wrzesinska A, Le Bihan MC, Thaysen-Andersen M, Roepstorff P. 2D gels still have a niche in proteomics. J Proteomics (2013) 88:4-13. doi:10.1016/j.jprot.2013.01.010
20. Tan HT, Lee YH, Chung MC. Cancer proteomics. Mass Spectrom Rev (2012) 31:583-605. doi:10.1002/mas.20356
21. Chen Y-T, Chen H-W, Domanski D, Smith DS, Liang K-H, Wu C-C, et al. Multiplexed quantification of 63 proteins in human urine by multiple reaction monitoring-based mass spectrometry for discovery of potential bladder cancer biomarkers. J Proteomics (2012) 75:3529-45. doi:10.1016/j.jprot.2011.12.031
22. Abbatiello SE, Schilling B, Mani DR, Zimmerman LJ, Hall SC, MacLean B, et al. Large-scale interlaboratory study to develop, analytically validate and apply highly multiplexed, quantitative peptide assays to measure cancer-relevant proteins in plasma. Mol Cell Proteomics (2015) 14:2357-74. doi:10.1074/mcp.M114.047050
23. Cawthorn TR, Moreno JC, Dharsee M, Tran-Thanh D, Ackloo S, Zhu PH, et al. Proteomic analyses reveal high expression of decorin and endoplasmin (HSP90B1) are associated with breast cancer metastasis and decreased survival. PLoS One (2012) 7:e30992. doi:10.1371/journal.pone.0030992
24. Cohen A, Wang E, Chisholm KA, Kostyleva R, O'Connor-McCourt M, Pinto DM. A mass spectrometry-based plasma protein panel targeting the tumor microenvironment in patients with breast cancer. J Proteomics (2013) 81:135-47. doi:10.1016/j.jprot.2012.11.004
25. De Marchi T, Kuhn E, Dekker LJ, Stingl C, Braakman RB, Opdam M, et al. Targeted MS assay predicting tamoxifen resistance in estrogen-receptor-positive breast cancer tissues and sera. J Proteome Res (2016) 15:1230-42. doi:10.1021/acs.jproteome.5b01119
26. Kennedy JJ, Abbatiello SE, Kim K, Yan P, Whiteaker JR, Lin C, et al. Demonstrating the feasibility of large-scale development of standardized assays to quantify human proteins. Nat Methods (2013) 11:149-55. doi:10.1038/nmeth.2763
27. Muraoka S, Kume H, Watanabe S, Adachi J, Kuwano M, Sato M, et al. Strategy for SRM-based verification of biomarker candidates discovered by iTRAQ method in limited breast cancer tissue samples. J Proteome Res (2012) 11:4201-10. doi:10.1021/pr300322q
28. Narumi R, Murakami T, Kuga T, Adachi J, Shiromizu T, Muraoka S, et al. A strategy for large-scale phosphoproteomics and SRM-based validation of human breast cancer tissue samples. J Proteome Res (2012) 11:5311-22. doi:10.1021/pr3005474
29. Pavlou MP, Dimitromanolakis A, Martinez-Morillo E, Smid M, Foekens JA, Diamandis EP. Integrating meta-analysis of microarray data and targeted proteomics for biomarker identification: application in breast cancer. J Proteome Res (2014) 13:2897-909. doi:10.1021/pr500352e
30. Riley CP, Zhang X, Nakshatri H, Schneider B, Regnier FE, Adamec J, et al. A large, consistent plasma proteomics data set from prospectively collected breast cancer patient and healthy volunteer samples. J Transl Med (2011) 9:80. doi:10.1186/1479-5876-9-80
31. Shaheed S, Rustogi N, Scally A, Wilson J, Thygesen H, Loizidou MA, et al. Identification of stage-specific breast markers using quantitative proteomics. J Proteome Res (2013) 12:5696-708. doi:10.1021/pr400662k
32. Steiner C, Tille J-C, Lamerz J, Kux van Geijtenbeek S, McKee TA, Venturi M, et al. Quantification of HER2 by targeted mass spectrometry in formalin-fixed paraffin-embedded breast cancer tissues. Mol Cell Proteomics (2015) 14(10):2786-99. doi:10.1074/mcp.O115.049049
33. Such-Sanmartín G, Bache N, Callesen AK, Rogowska-Wrzesinska A, Jensen ON. Targeted mass spectrometry analysis of the proteins IGF1, IGF2, IBP2, IBP3 and A2GL by blood protein precipitation. J Proteomics (2015) 113:29-37. doi:10.1016/j.jprot.2014.09.013
34. Umar A, Kang H, Timmermans AM, Look MP, Meijer-van Gelder ME, den Bakker MA, et al. Identification of a putative protein profile associated with tamoxifen therapy resistance in breast cancer. Mol Cell Proteomics (2009) 8:1278-94. doi:10.1074/mcp.M800493-MCP200
35. van den Broek I, Sparidans RW, Schellens JH, Beijnen JH. Quantitative assay for six potential breast cancer biomarker peptides in human serum by liquid chromatography coupled to tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2010) 878:590-602. doi:10.1016/j.jchromb.2010.01.011
36. Xu Q, Zhu M, Yang T, Xu F, Liu Y, Chen Y. Quantitative assessment of human serum transferrin receptor in breast cancer patients pre- and post-chemotherapy using peptide immunoaffinity enrichment coupled with targeted proteomics. Clin Chim Acta (2015) 448:118-23. doi:10.1016/j.cca.2015.05.022
37. Yang T, Chen F, Xu F, Wang F, Xu Q, Chen Y. A liquid chromatography-tandem mass spectrometry-based targeted proteomics assay for monitoring P-glycoprotein levels in human breast tissue. Clin Chim Acta (2014) 436:283-9. doi:10.1016/j.cca.2014.06.013
38. Ang C-S, Nice EC. Targeted In-gel MRM: a hypothesis driven approach for colorectal cancer biomarker discovery in human feces. J Proteome Res (2010) 9:4346-55. doi:10.1021/pr100509e
39. Bertuzzi M, Marelli C, Bagnati R, Colombi A, Fanelli R, Saieva C, et al. Plasma clusterin as a candidate pre-diagnosis marker of colorectal cancer risk in the Florence cohort of the European Prospective Investigation into cancer and nutrition: a pilot study. BMC Cancer (2015) 15:56. doi:10.1186/s12885-015-1058-7
40. Brock R, Xiong B, Li L, VanBogelen RA, Christman L. A multiplex serum protein assay for determining the probability of colorectal cancer. Am J Cancer Res (2012) 2:598-605.
41. Bröker MEE, Lalmahomed ZS, Roest HP, van Huizen NA, Dekker LJM, Calame W, et al. Collagen peptides in urine: a new promising biomarker for the detection of colorectal liver metastases. PLoS One (2013) 8:e70918. doi:10.1371/journal.pone.0070918
42. Chen Y, Gruidl M, Remily-Wood E, Liu RZ, Eschrich S, Lloyd M, et al. Quantification of ß-catenin signaling components in colon cancer cell lines, tissue sections, and microdissected tumor cells using reaction monitoring mass spectrometry. J Proteome Res (2010) 9:4215-27. doi:10.1021/pr1005197
43. Kume H, Muraoka S, Kuga T, Adachi J, Narumi R, Watanabe S, et al. Discovery of colorectal cancer biomarker candidates by membrane proteomic analysis and subsequent verification using selected reaction monitoring (SRM) and tissue microarray (TMA) analysis. Mol Cell Proteomics (2014) 13:1471-84. doi:10.1074/mcp.M113.037093
44. Yin HR, Zhang L, Xie LQ, Huang LY, Xu Y, Cai SJ, et al. Hyperplex-MRM: a hybrid multiple reaction monitoring method using mTRAQ/iTRAQ labeling for multiplex absolute quantification of human colorectal cancer biomarker. J Proteome Res (2013) 12:3912-9. doi:10.1021/pr4005025
45. DeSouza LV, Taylor AM, Li W, Minkoff MS, Romaschin AD, Colgan TJ, et al. Multiple reaction monitoring of mTRAQ-labeled peptides enables absolute quantification of endogenous levels of a potential cancer marker in cancerous and normal endometrial tissues. J Proteome Res (2008) 7:3525-34. doi:10.1021/pr800312m
46. Catenacci DVT, Liao W-L, Thyparambil S, Henderson L, Xu P, Zhao L, et al. Absolute quantitation of Met using mass spectrometry for clinical application: assay precision, stability, and correlation with MET gene amplification in FFPE tumor tissue. PLoS One (2014) 9:e100586. doi:10.1371/journal.pone.0100586
47. Demeure K, Fack F, Duriez E, Tiemann K, Bernard A, Golebiewska A, et al. Targeted proteomics to assess the response to anti-angiogenic treatment in human glioblastoma. Mol Cell Proteomics (2015) 15(2):481-92. doi:10.1074/mcp.M115.052423
48. Guo T, Kouvonen P, Koh CC, Gillet LC, Wolski WE, Röst HL, et al. Rapid mass spectrometric conversion of tissue biopsy samples into permanent quantitative digital proteome maps. Nat Med (2015) 21:407-13. doi:10.1038/nm.3807
49. Ahn YH, Shin PM, Oh NR, Park GW, Kim H, Yoo JS. A lectin-coupled, targeted proteomic mass spectrometry (MRM MS) platform for identification of multiple liver cancer biomarkers in human plasma. J Proteomics (2012) 75:5507-15. doi:10.1016/j.jprot.2012.06.027
50. Ahn YH, Shin PM, Kim Y-S, Oh NR, Ji ES, Kim KH, et al. Quantitative analysis of aberrant protein glycosylation in liver cancer plasma by AAL-enrichment and MRM mass spectrometry. Analyst (2013) 138:6454-62. doi:10.1039/c3an01126g
51. Kim H, Kim K, Yu SJ, Jang ES, Yu J, Cho G, et al. Development of biomarkers for screening hepatocellular carcinoma using global data mining and multiple reaction monitoring. PLoS One (2013) 8:e63468. doi:10.1371/journal.pone.0063468
52. Kim H, Kim K, Jin J, Park J, Yu SJ, Yoon JH, et al. Measurement of glycosylated alpha-fetoprotein improves diagnostic power over the native form in hepatocellular carcinoma. PLoS One (2014) 9:e110366. doi:10.1371/journal.pone.0110366
53. Kim JY, Oh D, Kim S-K, Kang D, Moon MH. Isotope-coded carbamidomethylation for quantification of N-glycoproteins with online microbore hollow fiber enzyme reactor-nanoflow liquid chromatography-tandem mass spectrometry. Anal Chem (2014) 86:7650-7. doi:10.1021/ac501544r
54. Lee JY, Kim JY, Park GW, Cheon MH, Kwon K-H, Ahn YH, et al. Targeted mass spectrometric approach for biomarker discovery and validation with nonglycosylated tryptic peptides from N-linked glycoproteins in human plasma. Mol Cell Proteomics (2011) 10:M111.009290. doi:10.1074/mcp.M111.009290
55. Lee JY, Kim JY, Cheon MH, Park GW, Ahn YH, Moon MH, et al. MRM validation of targeted nonglycosylated peptides from N-glycoprotein biomarkers using direct trypsin digestion of undepleted human plasma. J Proteomics (2014) 98:206-17. doi:10.1016/j.jprot.2014.01.003
56. Mustafa MG, Petersen JR, Ju H, Cicalese L, Snyder N, Haidacher SJ, et al. Biomarker discovery for early detection of hepatocellular carcinoma in hepatitis C-infected patients. Mol Cell Proteomics (2013) 12:3640-52. doi:10.1074/mcp.M113.031252
57. Mustafa GM, Larry D, Petersen JR, Elferink CJ. Targeted proteomics for biomarker discovery and validation of hepatocellular carcinoma in hepatitis C infected patients. World J Hepatol (2015) 7:1312. doi:10.4254/wjh.v7.i10.1312
58. Naboulsi W, Megger DA, Bracht T, Kohl M, Turewicz M, Eisenacher M, et al. Quantitative tissue proteomics analysis reveals versican as potential biomarker for early-stage hepatocellular carcinoma. J Proteome Res (2016) 15:38-47. doi:10.1021/acs.jproteome.5b00420
59. Sanda M, Pompach P, Brnakova Z, Wu J, Makambi K, Goldman R. Quantitative liquid chromatography-mass spectrometry-multiple reaction monitoring (LC-MS-MRM) analysis of site-specific glycoforms of haptoglobin in liver disease. Mol Cell Proteomics (2013) 12:1294-305. doi:10.1074/mcp.M112.023325
60. Zhao Y, Jia W, Sun W, Jin W, Guo L, Wei J, et al. Combination of improved (18)O incorporation and multiple reaction monitoring: a universal strategy for absolute quantitative verification of serum candidate biomarkers of liver cancer. J Proteome Res (2010) 9:3319-27. doi:10.1021/pr9011969
61. Ahn YH, Ji ES, Oh NR, Kim Y-S, Ko JH, Yoo JS. Differential proteomic approach for identification and verification of aberrantly glycosylated proteins in adenocarcinoma lung cancer (ADLC) plasmas by lectin-capturing and targeted mass spectrometry. J Proteomics (2014) 106:221-9. doi:10.1016/j.jprot.2014.04.031
62. Chen C-D, Wang C-L, Yu C-J, Chien K-Y, Chen Y-T, Chen M-C, et al. Targeted proteomics pipeline reveals potential biomarkers for the diagnosis of metastatic lung cancer in pleural effusion. J Proteome Res (2014) 13:2818-29. doi:10.1021/pr4012377
63. Fang B, Hoffman MA, Mirza AS, Mishall KM, Li J, Peterman SM, et al. Evaluating kinase ATP uptake and tyrosine phosphorylation using multiplexed quantification of chemically labeled and post-translationally modified peptides. Methods (2015) 81:41-9. doi:10.1016/j.ymeth.2015.03.006
64. Hembrough T, Thyparambil S, Liao W-L, Darfler MM, Abdo J, Bengali KM, et al. Selected reaction monitoring (SRM) analysis of epidermal growth factor receptor (EGFR) in formalin fixed tumor tissue. Clin Proteomics (2012) 9:5. doi:10.1186/1559-0275-9-5
65. Kim YJ, Sertamo K, Pierrard M-A, Mesmin C, Kim SY, Schlesser M, et al. Verification of the biomarker candidates for non-small-cell lung cancer using a targeted proteomics approach. J Proteome Res (2015) 14:1412-9. doi:10.1021/pr5010828
66. Li XJ, Hayward C, Fong P-Y, Dominguez M, Hunsucker SW, Lee LW, et al. A blood-based proteomic classifier for the molecular characterization of pulmonary nodules. Sci Transl Med (2013) 5:207ra142. doi:10.1126/scitranslmed.3007013
67. Nicol GR, Han M, Kim J, Birse CE, Brand E, Nguyen A, et al. Use of an immunoaffinity-mass spectrometry-based approach for the quantification of protein biomarkers from serum samples of lung cancer patients. Mol Cell Proteomics (2008) 7:1974-82. doi:10.1074/mcp.M700476-MCP200
68. Nishimura T, Nomura M, Tojo H, Hamasaki H, Fukuda T, Fujii K, et al. Proteomic analysis of laser-microdissected paraffin-embedded tissues: (2) MRM assay for stage-related proteins upon non-metastatic lung adenocarcinoma. J Proteomics (2010) 73:1100-10. doi:10.1016/j.jprot.2009.11.010
69. Ortea I, Rodríguez-Ariza A, Chicano-Gálvez E, Arenas Vacas MS, Jurado Gámez B. Discovery of potential protein biomarkers of lung adenocarcinoma in bronchoalveolar lavage fluid by SWATH MS data-independent acquisition and targeted data extraction. J Proteomics (2016) 138:106-14. doi:10.1016/j.jprot.2016.02.010
70. Park J, Yang JS, Jung G, Woo HI, Park HD, Kim JW, et al. Subunit-specific mass spectrometry method identifies haptoglobin subunit alpha as a diagnostic marker in non-small cell lung cancer. J Proteomics (2013) 94:302-10. doi:10.1016/j.jprot.2013.09.019
71. Sung HJ, Jeon SA, Ahn JM, Seul KJ, Kim JY, Lee JY, et al. Large-scale isotype-specific quantification of serum amyloid A 1/2 by multiple reaction monitoring in crude sera. J Proteomics (2012) 75:2170-80. doi:10.1016/j.jprot.2012.01.018
72. Torsetnes SB, Levernaes MS, Broughton MN, Paus E, Halvorsen TG, Reubsaet L. Multiplexing determination of small cell lung cancer biomarkers and their isovariants in serum by immunocapture LC-MS/MS. Anal Chem (2014) 86:6983-92. doi:10.1021/ac500986t
73. Zhang H, Liu Q, Zimmerman LJ, Ham A-JL, Slebos RJC, Rahman J, et al. Methods for peptide and protein quantitation by liquid chromatography-multiple reaction monitoring mass spectrometry. Mol Cell Proteomics (2011) 10:M110.006593. doi:10.1074/mcp.M110.006593
74. Paraiso KHT, Xiang Y, Rebecca VW, Abel EV, Chen YA, Munko AC, et al. PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res (2011) 71:2750-60. doi:10.1158/0008-5472.CAN-10-2954
75. Rebecca VW, Wood E, Fedorenko IV, Paraiso KH, Haarberg HE, Chen Y, et al. Evaluating melanoma drug response and therapeutic escape with quantitative proteomics. Mol Cell Proteomics (2014) 13:1844-54. doi:10.1074/mcp.M113.037424
76. Welinder C, Jönsson GB, Ingvar C, Lundgren L, Baldetorp B, Olsson H, et al. Analysis of alpha-synuclein in malignant melanoma - development of a SRM quantification assay. PLoS One (2014) 9:e110804. doi:10.1371/journal.pone.0110804
77. Cerciello F, Choi M, Nicastri A, Bausch-Fluck D, Ziegler A, Vitek O, et al. Identification of a seven glycopeptide signature for malignant pleural mesothelioma in human serum by selected reaction monitoring. Clin Proteomics (2013) 10:1. doi:10.1186/1559-0275-10-16
78. Kawahara R, Bollinger JG, Rivera C, Ribeiro ACP, Brandão TB, Leme AFP, et al. A targeted proteomic strategy for the measurement of oral cancer candidate biomarkers in human saliva. Proteomics (2016) 16:159-73. doi:10.1002/pmic.201500224
79. Drabovich AP, Diamandis EP. Combinatorial peptide libraries facilitate development of multiple reaction monitoring assays for low-abundance proteins. J Proteome Res (2010) 9:1236-45. doi:10.1021/pr900729g
80. Haslene-Hox H, Oveland E, Woie K, Salvesen HB, Wiig H, Tenstad O. Increased WD-repeat containing protein 1 in interstitial fluid from ovarian carcinomas shown by comparative proteomic analysis of malignant and healthy gynecological tissue. Biochim Biophys Acta (2013) 1834:2347-59. doi:10.1016/j.bbapap.2013.05.011
81. Huttenhain R, Soste M, Selevsek N, Rost H, Sethi A, Carapito C, et al. Reproducible quantification of cancer-associated proteins in body fluids using targeted proteomics. Sci Transl Med (2012) 4:142ra94. doi:10.1126/scitranslmed.3003989
82. Tang HY, Beer LA, Chang-Wong T, Hammond R, Gimotty P, Coukos G, et al. A xenograft mouse model coupled with in-depth plasma proteome analysis facilitates identification of novel serum biomarkers for human ovarian cancer. J Proteome Res (2012) 11:678-91. doi:10.1021/pr200603h
83. Tang HY, Beer LA, Tanyi JL, Zhang R, Liu Q, Speicher DW. Protein isoform-specific validation defines multiple chloride intracellular channel and tropomyosin isoforms as serological biomarkers of ovarian cancer. J Proteomics (2013) 89:165-78. doi:10.1016/j.jprot.2013.06.016
84. Halvey PJ, Ferrone CR, Liebler DC. GeLC-MRM quantitation of mutant KRAS oncoprotein in complex biological samples. J Proteome Res (2012) 11:3908-13. doi:10.1021/pr300161j
85. Iuga C, Seicean A, Iancu C, Buiga R, Sappa PK, Völker U, et al. Proteomic identification of potential prognostic biomarkers in resectable pancreatic ductal adenocarcinoma. Proteomics (2014) 14:945-55. doi:10.1002/pmic.201300402
86. Kawahara T, Hotta N, Ozawa Y, Kato S, Kano K, Yokoyama Y, et al. Quantitative proteomic profiling identifies DPYSL3 as pancreatic ductal adenocarcinoma-associated molecule that regulates cell adhesion and migration by stabilization of focal adhesion complex. PLoS One (2013) 8:e79654. doi:10.1371/journal.pone.0079654
87. Kim Y, Kang M, Han D, Kim H, Lee K, Kim S-W, et al. Biomarker development for intraductal papillary mucinous neoplasms using multiple reaction monitoring mass spectrometry. J Proteome Res (2015) 15:100-13. doi:10.1021/acs.jproteome.5b00553
88. Nie S, Yin H, Tan Z, Anderson MA, Ruffin MT, Simeone DM, et al. Quantitative analysis of single amino acid variant peptides associated with pancreatic cancer in serum by an isobaric labeling quantitative method. J Proteome Res (2014) 13:6058-66. doi:10.1021/pr500934u
89. Ohmine K, Kawaguchi K, Ohtsuki S, Motoi F, Ohtsuka H, Kamiie J, et al. Quantitative targeted proteomics of pancreatic cancer: deoxycytidine kinase protein level correlates to progression-free survival of patients receiving gemcitabine treatment. Mol Pharm (2015) 12:3282-91. doi:10.1021/acs.molpharmaceut.5b00282
90. Pan S, Chen R, Brand RE, Hawley S, Tamura Y, Gafken PR, et al. Multiplex targeted proteomic assay for biomarker detection in plasma: a pancreatic cancer biomarker case study. J Proteome Res (2012) 11:1937-48. doi:10.1021/pr201117w
91. Takadate T, Onogawa T, Fukuda T, Motoi F, Suzuki T, Fujii K, et al. Novel prognostic protein markers of resectable pancreatic cancer identified by coupled shotgun and targeted proteomics using formalin-fixed paraffin-embedded tissues. Int J Cancer (2013) 132:1368-82. doi:10.1002/ijc.27797
92. Turtoi A, Musmeci D, Wang Y, Dumont B, Somja J, Bevilacqua G, et al. Identification of novel accessible proteins bearing diagnostic and therapeutic potential in human pancreatic ductal adenocarcinoma. J Proteome Res (2011) 10:4302-13. doi:10.1021/pr200527z
93. Wehr AY, Hwang W-T, Blair IA, Yu KH. Relative quantification of serum proteins from pancreatic ductal adenocarcinoma patients by stable isotope dilution liquid chromatography-mass spectrometry. J Proteome Res (2012) 11:1749-58. doi:10.1021/pr201011f
94. Yoneyama T, Ohtsuki S, Ono M, Ohmine K, Uchida Y, Yamada T, et al. Quantitative targeted absolute proteomics-based large-scale quantification of proline-hydroxylated a-fibrinogen in plasma for pancreatic cancer diagnosis. J Proteome Res (2013) 12:753-62. doi:10.1021/pr3008144
95. Adeola HA, Calder B, Soares NC, Kaestner L, Blackburn JM, Zerbini LF. In silico verification and parallel reaction monitoring prevalidation of potential prostate cancer biomarkers. Future Oncol (2016) 12:43-57. doi:10.2217/fon.15.296
96. Barnidge DR, Goodmanson MK, Klee GG, Muddiman DC. Absolute quantification of the model biomarker prostate-specific antigen in serum by LC-MS/MS using protein cleavage and isotope dilution mass spectrometry. J Proteome Res (2004) 3:644-52. doi:10.1021/pr049963d
97. Chen Y-T, Tuan L-P, Chen H-W, Wei I-A, Chou M-Y, Chen H-M, et al. Quantitative analysis of prostate specific antigen isoforms using immunoprecipitation and stable isotope labeling mass spectrometry. Anal Chem (2014) 87:545-53. doi:10.1021/ac5033066
98. Cima I, Schiess R, Wild P, Kaelin M, Schuffler P, Lange V, et al. Cancer genetics-guided discovery of serum biomarker signatures for diagnosis and prognosis of prostate cancer. Proc Natl Acad Sci U S A (2011) 108:3342-7. doi:10.1073/pnas.1013699108
99. Fortin T, Salvador A, Charrier JP, Lenz C, Lacoux X, Morla A, et al. Clinical quantitation of prostate-specific antigen biomarker in the low nanogram/milliliter range by conventional bore liquid chromatography-tandem mass spectrometry (multiple reaction monitoring) coupling and correlation with ELISA tests. Mol Cell Proteomics (2009) 8:1006-15. doi:10.1074/mcp.M800238-MCP200
100. Geisler C, Gaisa NT, Pfister D, Fuessel S, Kristiansen G, Braunschweig T, et al. Identification and validation of potential new biomarkers for prostate cancer diagnosis and prognosis using 2D-DIGE and MS. Biomed Res Int (2015) 2015:1-23. doi:10.1155/2015/454256
101. Liu Y, Chen J, Sethi A, Li QK, Chen L, Collins B, et al. Glycoproteomic analysis of prostate cancer tissues by SWATH mass spectrometry discovers N-acylethanolamine acid amidase and protein tyrosine kinase 7 as signatures for tumor aggressiveness. Mol Cell Proteomics (2014) 13:1753-68. doi:10.1074/mcp.M114.038273
102. Shi T, Sun X, Gao Y, Fillmore TL, Schepmoes AA, Zhao R, et al. Targeted quantification of low ng/mL level proteins in human serum without immunoaffinity depletion. J Proteome Res (2013) 12:3353-61. doi:10.1021/pr400178v
103. Shi T, Gao Y, Quek SI, Fillmore TL, Nicora CD, Su D, et al. A highly sensitive targeted mass spectrometric assay for quantification of AGR2 protein in human urine and serum. J Proteome Res (2014) 13:875-82. doi:10.1021/pr400912c
104. Templeton AJ, Dutoit V, Cathomas R, Rothermundt C, Bärtschi D, Dröge C, et al. Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08). Eur Urol (2013) 64:150-8. doi:10.1016/j.eururo.2013.03.040
105. Vegvari A, Sjodin K, Rezeli M, Malm J, Lilja H, Laurell T, et al. Identification of a novel proteoform of prostate specific antigen (SNP-L132I) in clinical samples by multiple reaction monitoring. Mol Cell Proteomics (2013) 12:2761-73. doi:10.1074/mcp.M113.028365
106. Martínez-Aguilar J, Clifton-Bligh R, Molloy MP. A multiplexed, targeted mass spectrometry assay of the S100 protein family uncovers the isoform-specific expression in thyroid tumours. BMC Cancer (2015) 15:199. doi:10.1186/s12885-015-1217-x
107. Abelin JG, Patel J, Lu X, Feeney CM, Fagbami L, Creech AL, et al. Reduced-representation phosphosignatures measured by quantitative targeted MS capture cellular states and enable large-scale comparison of drug-induced phenotypes. Mol Cell Proteomics (2016) 15:1622-41. doi:10.1074/mcp.M116.058354
108. Biarc J, Gonzalo P, Mikaelian I, Fattet L, Deygas M, Gillet G, et al. Combination of a discovery LC-MS/MS analysis and a label-free quantification for the characterization of an epithelial-mesenchymal transition signature. J Proteomics (2014) 110:183-94. doi:10.1016/j.jprot.2014.05.026
109. Domanski D, Murphy LC, Borchers CH. Assay development for the determination of phosphorylation stoichiometry using multiple reaction monitoring methods with and without phosphatase treatment: application to breast cancer signaling pathways. Anal Chem (2010) 82:5610-20. doi:10.1021/ac1005553
110. Drabovich AP, Pavlou MP, Dimitromanolakis A, Diamandis EP. Quantitative analysis of energy metabolic pathways in MCF-7 breast cancer cells by selected reaction monitoring assay. Mol Cell Proteomics (2012) 11:422-34. doi:10.1074/mcp.M111.015214
111. Dun MD, Chalkley RJ, Faulkner S, Keene S, Avery-Kiejda KA, Scott RJ, et al. Proteotranscriptomic profiling of 231-BR breast cancer cells: identification of potential biomarkers and therapeutic targets for brain metastasis. Mol Cell Proteomics (2015) 14:2316-30. doi:10.1074/mcp.M114.046110
112. Guo L, Xiao Y, Fan M, Li JJ, Wang Y. Profiling global kinome signatures of the radioresistant MCF-7/C6 breast cancer cells using MRM-based targeted proteomics. J Proteome Res (2015) 14:193-201. doi:10.1021/pr500919w
113. Held JM, Schilling B, D'Souza AK, Srinivasan T, Behring JB, Sorensen DJ, et al. Label-free quantitation and mapping of the ErbB2 tumor receptor by multiple protease digestion with data-dependent (MS1) and data-independent (MS2) acquisitions. Int J Proteomics (2013) 2013:1-11. doi:10.1155/2013/791985
114. Ishiba T, Nagahara M, Nakagawa T, Sato T, Ishikawa T, Uetake H, et al. Periostin suppression induces decorin secretion leading to reduced breast cancer cell motility and invasion. Sci Rep (2014) 4:7069. doi:10.1038/srep07069
115. Leong S, McKay MJ, Christopherson RI, Baxter RC. Biomarkers of breast cancer apoptosis induced by chemotherapy and TRAIL. J Proteome Res (2012) 11:1240-50. doi:10.1021/pr200935y
116. Murphy JP, Pinto DM. Temporal proteomic analysis of IGF-1R signalling in MCF-7 breast adenocarcinoma cells. Proteomics (2010) 10:1847-60. doi:10.1002/pmic.200900711
117. Sandhu C, Hewel JA, Badis G, Talukder S, Liu J, Hughes TR, et al. Evaluation of data-dependent versus targeted shotgun proteomic approaches for monitoring transcription factor expression in breast cancer. J Proteome Res (2008) 7:1529-41. doi:10.1021/pr700836q
118. Whiteaker JR, Zhang H, Zhao L, Wang P, Kelly-Spratt KS, Ivey RG, et al. Integrated pipeline for mass spectrometry-based discovery and confirmation of biomarkers demonstrated in a mouse model of breast cancer. J Proteome Res (2007) 6:3962-75. doi:10.1021/pr070202v
119. Ahn YH, Kim Y-S, Ji ES, Lee JY, Jung J-A, Ko JH, et al. Comparative quantitation of aberrant glycoforms by lectin-based glycoprotein enrichment coupled with multiple-reaction monitoring mass spectrometry. Anal Chem (2010) 82:4441-7. doi:10.1021/ac1001965
120. Ivancic MM, Huttlin EL, Chen X, Pleiman JK, Irving AA, Hegeman AD, et al. Candidate serum biomarkers for early intestinal cancer using 15N metabolic labeling and quantitative proteomics in the ApcMin/+ mouse. J Proteome Res (2013) 12:4152-66. doi:10.1021/pr400467c
121. Rangiah K, Tippornwong M, Sangar V, Austin D, Tétreault M-P, Rustgi AK, et al. Differential secreted proteome approach in murine model for candidate biomarker discovery in colon cancer. J Proteome Res (2009) 8:5153-64. doi:10.1021/pr900518v
122. Remily-Wood ER, Liu RZ, Xiang Y, Chen Y, Thomas CE, Rajyaguru N, et al. A database of reaction monitoring mass spectrometry assays for elucidating therapeutic response in cancer. Proteomics Clin Appl (2011) 5:383-96. doi:10.1002/prca.201000115
123. Sangar V, Funk CC, Kusebauch U, Campbell DS, Moritz RL, Price ND. Quantitative proteomic analysis reveals effects of epidermal growth factor receptor (EGFR) on invasion-promoting proteins secreted by glioblastoma cells. Mol Cell Proteomics (2014) 13:2618-31. doi:10.1074/mcp.M114.040428
124. Rafalko A, Iliopoulos O, Fusaro VA, Hancock W, Hincapie M. Immunoaffinity enrichment and liquid chromatography-selected reaction monitoring mass spectrometry for quantitation of carbonic anhydrase 12 in cultured renal carcinoma cells. Anal Chem (2010) 82:8998-9005. doi:10.1021/ac101981t
125. Sprung RW, Martinez MA, Carpenter KL, Ham AJ, Washington MK, Arteaga CL, et al. Precision of multiple reaction monitoring mass spectrometry analysis of formalin-fixed, paraffin-embedded tissue. J Proteome Res (2012) 11:3498-505. doi:10.1021/pr300130t
126. Alcolea MP, Casado P, Rodriguez-Prados JC, Vanhaesebroeck B, Cutillas PR. Phosphoproteomic analysis of leukemia cells under basal and drug-treated conditions identifies markers of kinase pathway activation and mechanisms of resistance. Mol Cell Proteomics (2012) 11:453-66. doi:10.1074/mcp.M112.017483
127. Assiddiq BF, Tan KY, Toy W, Chan SP, Chong PK, Lim YP. EGFR S1166 phosphorylation induced by a combination of EGF and gefitinib has a potentially negative impact on lung cancer cell growth. J Proteome Res (2012) 11:4110-9. doi:10.1021/pr3002029
128. Kim H-J, Lin D, Li M, Liebler DC. Quantitative profiling of protein tyrosine kinases in human cancer cell lines by multiplexed parallel reaction monitoring assays. Mol Cell Proteomics (2015) 15:682-91. doi:10.1074/mcp.O115.051813
129. Xiang Y, Remily-Wood ER, Oliveira V, Yarde D, He L, Cheng JQ, et al. Monitoring a nuclear factor ?B signature of drug resistance in multiple myeloma. Mol Cell Proteomics (2011) 10:M110.005520. doi:10.1074/mcp.M110.005520
130. Beer LA, Wang H, Tang H-Y, Cao Z, Chang-Wong T, Tanyi JL, et al. Identification of multiple novel protein biomarkers shed by human serous ovarian tumors into the blood of immunocompromised mice and verified in patient sera. PLoS One (2013) 8:e60129. doi:10.1371/journal.pone.0060129
131. Kim JW, Nie B, Sahm H, Brown DP, Tegeler T, You J-S, et al. Targeted quantitative analysis of superoxide dismutase 1 in cisplatin-sensitive and cisplatin-resistant human ovarian cancer cells. J Chromatogr B Analyt Technol Biomed Life Sci (2010) 878:700-4. doi:10.1016/j.jchromb.2010.01.013
132. Kimura A, Arakawa N, Hirano H. Mass spectrometric analysis of the phosphorylation levels of the SWI/SNF chromatin remodeling/tumor suppressor proteins ARID1A and Brg1 in ovarian clear cell adenocarcinoma cell lines. J Proteome Res (2014) 13:4959-69. doi:10.1021/pr500470h
133. He J, Schepmoes AA, Shi T, Wu C, Fillmore TL, Gao Y, et al. Analytical platform evaluation for quantification of ERG in prostate cancer using protein and mRNA detection methods. J Transl Med (2015) 13:54. doi:10.1186/s12967-015-0418-z
134. Nwabo Kamdje AH, Seke Etet PF, Vecchio L, Muller JM, Krampera M, Lukong KE. Signaling pathways in breast cancer: therapeutic targeting of the microenvironment. Cell Signal (2014) 26:2843-56. doi:10.1016/j.cellsig.2014.07.034
135. Ellis MJ, Gillette M, Carr SA, Paulovich AG, Smith RD, Rodland KK, et al. Connecting genomic alterations to cancer biology with proteomics: the NCI clinical proteomic tumor analysis consortium. Cancer Discov (2013) 3:1108-12. doi:10.1158/2159-8290.CD-13-0219
136. Boersema PJ, Aye TT, van Veen TA, Heck AJ, Mohammed S. Triplex protein quantification based on stable isotope labeling by peptide dimethylation applied to cell and tissue lysates. Proteomics (2008) 8:4624-32. doi:10.1002/pmic.200800297
137. Boja ES, Rodriguez H. Proteogenomic convergence for understanding cancer pathways and networks. Clin Proteomics (2014) 11:22. doi:10.1186/1559-0275-11-22
138. Chen EI, Yates JR. Cancer proteomics by quantitative shotgun proteomics. Mol Oncol (2007) 1:144-59. doi:10.1016/j.molonc.2007.05.001
139. Edwards AM, Isserlin R, Bader GD, Frye SV, Willson TM, Yu FH. Too many roads not taken. Nature (2011) 470:163-5. doi:10.1038/470163a
140. Desiderio DM, Kai M. Preparation of stable isotope-incorporated peptide internal standards for field desorption mass spectrometry quantification of peptides in biologic tissue. Biol Mass Spectrom (1983) 10:471-9.
141. Kusmierz JJ, Sumrada R, Desiderio DM. Fast atom bombardment mass spectrometric quantitative analysis of methionine-enkephalin in human pituitary tissues. Anal Chem (1990) 62:2395-400.
142. Domon B, Gallien S. Recent advances in targeted proteomics for clinical applications. Proteomics Clin Appl (2015) 9:423-31. doi:10.1002/prca.201400136
143. Gallien S, Duriez E, Domon B. Selected reaction monitoring applied to proteomics. J Mass Spectrom (2011) 46:298-312. doi:10.1002/jms.1895
144. Ebhardt HA, Root A, Sander C, Aebersold R. Applications of targeted proteomics in systems biology and translational medicine. Proteomics (2015) 15(18):3193-208. doi:10.1002/pmic.201500004
145. Domon B, Aebersold R. Options and considerations when selecting a quantitative proteomics strategy. Nat Biotechnol (2010) 28:710-21. doi:10.1038/nbt.1661
146. Picotti P, Clément-Ziza M, Lam H, Campbell DS, Schmidt A, Deutsch EW, et al. A complete mass-spectrometric map of the yeast proteome applied to quantitative trait analysis. Nature (2013) 494:266-70. doi:10.1038/nature11835
147. Peterson AC, Russell JD, Bailey DJ, Westphall MS, Coon JJ. Parallel reaction monitoring for high resolution and high mass accuracy quantitative, targeted proteomics. Mol Cell Proteomics (2012) 11:1475-88. doi:10.1074/mcp.O112.020131
148. Percy AJ, Chambers AG, Yang J, Hardie DB, Borchers CH. Advances in multiplexed MRM-based protein biomarker quantitation toward clinical utility. Biochim Biophys Acta (2014) 1844:917-26. doi:10.1016/j.bbapap.2013.06.008
149. Gerber SA, Rush J, Stemman O, Kirschner MW, Gygi SP. Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS. Proc Natl Acad Sci U S A (2003) 100:6940-5. doi:10.1073/pnas.0832254100
150. Keshishian H, Addona T, Burgess M, Kuhn E, Carr SA. Quantitative, multiplexed assays for low abundance proteins in plasma by targeted mass spectrometry and stable isotope dilution. Mol Cell Proteomics (2007) 6:2212-29. doi:10.1074/mcp.M700354-MCP200
151. Aebersold R, Bensimon A, Collins BC, Ludwig C, Sabido E. Applications and developments in targeted proteomics: from SRM to DIA/SWATH. Proteomics (2016) 16:2065-7. doi:10.1002/pmic.201600203
152. Rosenberger G, Koh CC, Guo T, Röst HL, Kouvonen P, Collins BC, et al. A repository of assays to quantify 10,000 human proteins by SWATH-MS. Sci Data (2014) 1:140031. doi:10.1038/sdata.2014.31
153. Drapkin R, von Horsten HH, Lin Y, Mok SC, Crum CP, Welch WR, et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res (2005) 65:2162-9. doi:10.1158/0008-5472.can-04-3924
154. Abbatiello SE, Mani DR, Schilling B, MacLean B, Zimmerman LJ, Feng X, et al. Design, implementation and multisite evaluation of a system suitability protocol for the quantitative assessment of instrument performance in liquid chromatography-multiple reaction monitoring-MS (LC-MRM-MS). Mol Cell Proteomics (2013) 12:2623-39. doi:10.1074/mcp.M112.027078
155. Lesur A, Domon B. Advances in high-resolution accurate mass spectrometry application to targeted proteomics. Proteomics (2015) 15:880-90. doi:10.1002/pmic.201400450
156. Paul D, Kumar A, Gajbhiye A, Santra MK, Srikanth R. Mass spectrometry-based proteomics in molecular diagnostics: discovery of cancer biomarkers using tissue culture. Biomed Res Int (2013) 2013:783131. doi:10.1155/2013/783131
157. Brusniak MY, Kwok ST, Christiansen M, Campbell D, Reiter L, Picotti P, et al. ATAQS: a computational software tool for high throughput transition optimization and validation for selected reaction monitoring mass spectrometry. BMC Bioinformatics (2011) 12:78. doi:10.1186/1471-2105-12-78
158. MacLean B, Tomazela DM, Shulman N, Chambers M, Finney GL, Frewen B, et al. Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics (2010) 26:966-8. doi:10.1093/bioinformatics/btq054
159. Martucci VL, Pacak K. Pheochromocytoma and paraganglioma: diagnosis, genetics, management, and treatment. Curr Probl Cancer (2014) 38:7-41. doi:10.1016/j.currproblcancer.2014.01.001
160. Cantor DI, Nice EC, Baker MS. Recent findings from the human proteome project: opening the mass spectrometry toolbox to advance cancer diagnosis, surveillance and treatment. Expert Rev Proteomics (2015) 12:279-93. doi:10.1586/14789450.2015.1040770
161. Strimbu K, Tavel JA. What are biomarkers? Curr Opin HIV AIDS (2010) 5:463-6. doi:10.1097/COH.0b013e32833ed177
162. Surinova S, Schiess R, Huttenhain R, Cerciello F, Wollscheid B, Aebersold R. On the development of plasma protein biomarkers. J Proteome Res (2011) 10:5-16. doi:10.1021/pr1008515
163. Poste G. Bring on the biomarkers. Nature (2011) 469:156-7. doi:10.1038/469156a
164. Tuck MK, Chan DW, Chia D, Godwin AK, Grizzle WE, Krueger KE, et al. Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group. J Proteome Res (2009) 8:113-7. doi:10.1021/pr800545q
165. Zimmerman LJ, Li M, Yarbrough WG, Slebos RJ, Liebler DC. Global stability of plasma proteomes for mass spectrometry-based analyses. Mol Cell Proteomics (2012) 11:M111.014340. doi:10.1074/mcp.M111.014340
166. Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics (2002) 1:845-67. doi:10.1074/mcp.R200007-MCP200
167. Picotti P, Aebersold R. Selected reaction monitoring-based proteomics: workflows, potential, pitfalls and future directions. Nat Methods (2012) 9:555-66. doi:10.1038/nmeth.2015
168. Greenwood C, Metodieva G, Al-Janabi K, Lausen B, Alldridge L, Leng L, et al. Stat1 and CD74 overexpression is co-dependent and linked to increased invasion and lymph node metastasis in triple-negative breast cancer. J Proteomics (2012) 75:3031-40. doi:10.1016/j.jprot.2011.11.033
169. Brouillette CG, Anantharamaiah GM, Engler JA, Borhani DW. Structural models of human apolipoprotein A-I: a critical analysis and review. Biochim Biophys Acta (2001) 1531:4-46. doi:10.1016/S1388-1981(01)00081-6
170. Daub H. Quantitative proteomics of kinase inhibitor targets and mechanisms. ACS Chem Biol (2015) 10:201-12. doi:10.1021/cb5008794
171. Zhu MY, Wang Y, Wang Y, Peng FL, Ou HX, Zheng X, et al. [Serum amyloid A promotes the inflammatory response via p38-MAPK/SR-BI pathway in THP-1 macrophages]. Sheng Li Xue Bao (2016) 68:293-300. doi:10.13294/j.aps.2016.0029
172. Yang Y, Chen Y, Saha MN, Chen J, Evans K, Qiu L, et al. Targeting phospho-MARCKS overcomes drug-resistance and induces antitumor activity in preclinical models of multiple myeloma. Leukemia (2015) 29:715-26. doi:10.1038/leu.2014.255
173. Potts GK, Voigt EA, Bailey DJ, Rose CM, Westphall MS, Hebert AS, et al. Neucode labels for multiplexed, absolute protein quantification. Anal Chem (2016) 88:3295-303. doi:10.1021/acs.analchem.5b04773
174. Dephoure N, Gygi SP. Hyperplexing: a method for higher-order multiplexed quantitative proteomics provides a map of the dynamic response to rapamycin in yeast. Sci Signal (2012) 5:rs2. doi:10.1126/scisignal.2002548
175. Pavlou MP, Diamandis EP. The cancer cell secretome: a good source for discovering biomarkers? J Proteomics (2010) 73:1896-906. doi:10.1016/j.jprot.2010.04.003
176. Boja ES, Rodriguez H. Mass spectrometry-based targeted quantitative proteomics: achieving sensitive and reproducible detection of proteins. Proteomics (2012) 12:1093-110. doi:10.1002/pmic.201100387